The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome

Clinical Endocrinology

Volumn 67, Issue 6, 2007, Pages 904-908

  Sahin, Yilmaz ^a   Unluhizarci, Kursad ^a   Yilmazsoy, Ayse ^a   Yikilmaz, Ali ^a   Aygen, Ercan ^a   Kelestimur, Fahrettin ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTRADIOL; FOLLITROPIN; HOMOCYSTEINE; HYDROXYPROGESTERONE; INSULIN; LIPID; LIPOPROTEIN A; LUTEINIZING HORMONE; METFORMIN; PROGESTERONE; TESTOSTERONE;

ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN RESPONSE; LEAN BODY WEIGHT; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; CARDIOVASCULAR DISEASES; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; LUTEINIZING HORMONE; MENSTRUAL CYCLE; METFORMIN; POLYCYSTIC OVARY SYNDROME; PROGESTERONE; PROSPECTIVE STUDIES; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; YOUNG ADULT;

EID: 36249013118     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02985.x     Document Type: Article

References (34)

1. Legro, R.S. Myers, E. (2004) Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome? Human Reproduction, 19, 1967 1704.
2. Carmina, E., Longo, R.A., Rini, G.B. Lobo, R.A. (2005) Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. Journal of Clinical Endocrinology and Metabolism, 90, 2545 2549.
3. Vrbikova, J., Bendlova, B., Hill, M., Vankova, M., Vondra, K. Starka, L. (2002) Insulin sensitivity and β cell function in women with polycystic ovary syndrome. Diabetes Care, 25, 1217 1222.
4. Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group 2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 81, 19 25.
5. Hatch, R., Rosenfield, R.L., Kim, M.H. Tredway, D. (1981) Hirsutism: implications, etiology, and management. American Journal of Obstetrics and Gynecology, 140, 815 830.
6. Orsini, L.F., Venturoli, S., Lorusso, R., Pluchinotta, V., Paradisi, R. Bovicelli, L. (1985) Ultrasound findings in polycystic ovarian disease. Fertility and Sterility, 43, 709 714.
7. Bonora, E., Targher, G., Alberiche, M., Bonadonna, R.C., Saggiani, F., Zenere, M.B., Monauni, T. Muggeo, M. (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care, 23, 57 63.
8. The Expert Committee on the Diagnosis Classification of Diabetes Mellitus 1998) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 21 (Suppl. 1 S5 S19.
9. Wofford, J., Kahl, F., Howard, G., McKinney, W., Toole, J. Crouse, J. (1991) Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arteriosclerosis, Thrombosis and Vascular Biology, 11, 1786 1794.
10. Kanters, S., Algra, A. Van Leewen, M. (1997) Reproducibility of in vivo carotid intima-media thickness measurements. Stroke, 28, 665 671.
11. Dunaif, A. (1995) Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin dependent diabetes mellitus. American Journal of Medicine, 98, 33S 39S.
12. Morin-Papunen, L.C., Vauhkonen, I.M., Koivunen, R., Ruokonen, A. Tapanainen, J. (2000) Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovary syndrome. Human Reproduction, 15, 1266 1274.
13. Dunaif, A., Segal, K.R., Futterweit, W. Dobrjansky, A. (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes, 38, 1165 1174.
14. Morales, A.J., Laughlin, G.A., Butzow, T., Maheshwari, H., Baumann, G. Yen, S.S. (1996) Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. Journal of Clinical Endocrinology and Metabolism, 81, 2854 2864.
15. Holte, J., Bergh, T., Berne, C., Wide, L. Lithell, H. (1995) Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 80, 2586 2593.
16. Ovesen, P., Moller, J., Ingerslev, H.J., Jorgensen, J.O., Mengel, A., Schimitz, O., Alberti, K.G. Moller, N. (1993) Normal basal and insulin stimulated fuel metabolism in lean women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 77, 1636 1640.
17. Mansfield, R., Galea, R., Brincat, M., Hole, D. Mason, H. (2003) Metformin has direct effects on human ovarian steroidogenesis. Fertility and Sterility, 79, 956 962.
18. Wild, R.A., Painter, P.C., Coulson, P.B., Carruth, K.B. Ranney, G.B. (1985) Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 61, 946 951.
19. Robinson, S., Henderson, A.D., Gelding, S.V., Kiddy, D., Niththyanathan, R., Bush, A., Richmond, W., Johnston, D.G. Franks, S. (1996) Dyslipidemia is associated with insulin resistance in women with polycystic ovary syndrome. Clinical Endocrinology, 44, 277 284.
20. Talbott, E., Clerici, A., Berga, S.L., Kuller, L., Guzick, D., Detre, K., Daniels, T. Engberg, R.A. (1998) Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. Journal of Clinical Epidemiology, 51, 415 422.
21. Yilmaz, M., Idot, R., Idot, A., Bukan, N., Karakoc, A., Sancak, B., Toruner, F. Pasaoglu, H. (2005) Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecological Endocrinology, 20, 258 263.
22. Austin, M.A., Breslow, J.L., Hennekens, C.H., Buring, J.E., Willett, W.C. Krauss, R.M. (1988) Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA, 260, 1917 1921.
23. Azziz, R. (2003) We should avoid the indiscriminate use of insulin sensitizers in women with polycystic ovary syndrome. Fertility and Sterility, 80, 264 265.
24. Legro, R.S. (2003) Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocrine Reviews, 24, 302 312.
25. Salonen Jukka, T. Salonen, R. (1991) Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arteriosclerosis, Thrombosis and Vascular Biology, 11, 1245 1249.
26. Bots, M.L., Hoew, A.W., Koudstaal, P.J., Hofman, A. Grobbee, D.E. (1997) Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation, 96, 1432 1437.
27. Meyer, C., McGrath, P., Cameron, J., Kotsopoulos, D. Teede, H.J. (2005) Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 90, 4630 4635.
28. Zimmermann, S., Phillips, R.A., Dunaif, A., Finegood, D.T., Wilkenfeld, C., Gorlin, R. Krakoff, L.R. (1992) Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. Journal of Clinical Endocrinology and Metabolism, 75, 508 513.
29. Legro, R.S., Kunselman, A.R. Dunaif, A. (2001) Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. American Journal of Medicine, 111, 607 613.
30. Cattrall, F.R. Healy, D.L. (2004) Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome. Best Practice Research Clinical Obstetrics and Gynecology, 18, 803 812.
31. Genazzani, A.D., Petraglia, F., Pianazzi, F., Volpogni, C. Genazzani, A.R. (1993) The concomitant release of androstenedione with cortisol and luteinizing hormone pulsatile releases distinguishes adrenal from ovarian hyperandrogenism. Gynecological Endocrinology, 7, 33 41.
32. Morin-Papunen, L.C., Koivunen, R.M., Ruokonen, A. Martikainen, H.N. (1998) Metformin therapy improves the menstrual pattern with minimal endocrine effects in women with polycystic ovary syndrome. Fertility and Sterility, 69, 961 966.
33. Genazzani, A.D., Battaglia, C., Malavasi, B., Strucchi, C., Tortolani, F. Gamba, O. (2004) Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertility and Sterility, 81, 114 119.
34. Vrbikova, J., Hill, M., Starka, L., Cibula, D., Bendlova, B., Vondra, K., Sulcova, J. Snajderova, M. (2001) The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. European Journal of Endocrinology, 144, 619 628.